Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts
- PMID: 26453609
- PMCID: PMC4814183
- DOI: 10.1681/ASN.2015010068
Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts
Abstract
Hemodialysis vascular accesses are prone to recurrent stenosis and thrombosis after endovascular interventions.In vitro data suggest that indoxyl sulfate, a protein-bound uremic toxin, may induce vascular dysfunction and thrombosis. However, there is no clinical evidence regarding the role of indoxyl sulfate in hemodialysis vascular access. From January 2010 to June 2013, we prospectively enrolled patients undergoing angioplasty for dialysis access dysfunction. Patients were stratified into tertiles by baseline serum indoxyl sulfate levels. Study participants received clinical follow-up at 6-month intervals until June 2014. Primary end points were restenosis, thrombosis, and failure of vascular access. Median follow-up duration was 32 months. Of the 306 patients enrolled, 262 (86%) had symptomatic restenosis, 153 (50%) had access thrombosis, and 25 (8%) had access failure. In patients with graft access, free indoxyl sulfate tertiles showed a negative association with thrombosis-free patency (thrombosis-free patency rates of 54%, 38%, and 26% for low, middle, and high tertiles, respectively;P=0.001). Patients with graft thrombosis had higher free and total indoxyl sulfate levels. Using multivariate Cox regression analysis, graft thrombosis was independently predicted by absolute levels of free indoxyl sulfate (hazard ratio=1.14;P=0.01) and free indoxyl sulfate tertiles (high versus low, hazard ratio=2.41;P=0.001). Results of this study provide translational evidence that serum indoxyl sulfate is a novel risk factor for dialysis graft thrombosis after endovascular interventions.
Keywords: arteriovenous shunt; hemodialysis access; thrombosis.
Copyright © 2016 by the American Society of Nephrology.
Figures



Comment in
-
Dialysis Vascular Access Intervention and the Search for Biomarkers.J Am Soc Nephrol. 2016 Apr;27(4):970-2. doi: 10.1681/ASN.2015090982. Epub 2015 Oct 9. J Am Soc Nephrol. 2016. PMID: 26453612 Free PMC article. No abstract available.
Similar articles
-
Dialysis Vascular Access Intervention and the Search for Biomarkers.J Am Soc Nephrol. 2016 Apr;27(4):970-2. doi: 10.1681/ASN.2015090982. Epub 2015 Oct 9. J Am Soc Nephrol. 2016. PMID: 26453612 Free PMC article. No abstract available.
-
Impact of Indoxyl Sulfate on Progenitor Cell-Related Neovascularization of Peripheral Arterial Disease and Post-Angioplasty Thrombosis of Dialysis Vascular Access.Toxins (Basel). 2017 Jan 7;9(1):25. doi: 10.3390/toxins9010025. Toxins (Basel). 2017. PMID: 28067862 Free PMC article. Review.
-
Association of indoxyl sulfate with heart failure among patients on hemodialysis.Clin J Am Soc Nephrol. 2015 Jan 7;10(1):111-9. doi: 10.2215/CJN.04730514. Epub 2014 Oct 20. Clin J Am Soc Nephrol. 2015. PMID: 25332316 Free PMC article.
-
Myostatin Exacerbates Endothelial Dysfunction Induced by Uremic Toxin Indoxyl Sulfate and Is Associated with Hemodialysis Arteriovenous Access Complications.Toxins (Basel). 2025 Mar 22;17(4):159. doi: 10.3390/toxins17040159. Toxins (Basel). 2025. PMID: 40278657 Free PMC article.
-
Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies.Toxins (Basel). 2016 Nov 30;8(12):358. doi: 10.3390/toxins8120358. Toxins (Basel). 2016. PMID: 27916890 Free PMC article. Review.
Cited by
-
Dialysis Vascular Access Intervention and the Search for Biomarkers.J Am Soc Nephrol. 2016 Apr;27(4):970-2. doi: 10.1681/ASN.2015090982. Epub 2015 Oct 9. J Am Soc Nephrol. 2016. PMID: 26453612 Free PMC article. No abstract available.
-
The gut microbiota in thrombosis.Nat Rev Cardiol. 2025 Feb;22(2):121-137. doi: 10.1038/s41569-024-01070-6. Epub 2024 Sep 17. Nat Rev Cardiol. 2025. PMID: 39289543 Review.
-
Saikosaponin A protects against uremic toxin indole‑3 acetic acid‑induced damage to the myocardium.Mol Med Rep. 2023 Sep;28(3):159. doi: 10.3892/mmr.2023.13046. Epub 2023 Jul 7. Mol Med Rep. 2023. PMID: 37417356 Free PMC article.
-
Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.Toxins (Basel). 2018 Oct 12;10(10):412. doi: 10.3390/toxins10100412. Toxins (Basel). 2018. PMID: 30322010 Free PMC article. Review.
-
A Historical Perspective on Uremia and Uremic Toxins.Toxins (Basel). 2024 May 15;16(5):227. doi: 10.3390/toxins16050227. Toxins (Basel). 2024. PMID: 38787079 Free PMC article. Review.
References
-
- National Kidney Foundation-Dialysis Outcomes Quality Initiative : NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 30[Suppl 3]: S150–S191, 1997 - PubMed
-
- US Renal Data System: USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
-
- Roy-Chaudhury P, Sukhatme VP, Cheung AK: Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol 17: 1112–1127, 2006 - PubMed
-
- Schwab SJ, Oliver MJ, Suhocki P, McCann R: Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 59: 358–362, 2001 - PubMed
-
- Moist LM, Churchill DN, House AA, Millward SF, Elliott JE, Kribs SW, DeYoung WJ, Blythe L, Stitt LW, Lindsay RM: Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 14: 2645–2653, 2003 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical